A critical appraisal of "chronic lyme disease"

New England Journal of Medicine

Volumn 357, Issue 14, 2007, Pages 1422-

  Feder Jr , Henry M ^a,b   Johnson, Barbara J B ^c   O'Connell, Susan ^d   Shapiro, Eugene D ^e   Steere, Allen C ^f   Wormser, Gary P ^g   Agger, W A ^h   Artsob, H ⁱ   Auwaerter, P ^j   Dumler, J S ^j   Bakken, J S ^k   Bockenstedt, L K ^e   Green, J ^e   Dattwyler, R J ^g   Munoz, J ^g   Nadelman, R B ^g   Schwartz, I ^g   Draper, T ^l   McSweegan, E ^j   Halperin, J J ^m,n   Klempner, M S ^o   Krause, P J ^p   Mead, P ^q   Morshed, M ^r   Porwancher, R ^s   Radolf, J D ^b   Smith Jr , R P ^t   Sood, S ^u   Weinstein, A ^v   Wong, S J ^w   Zemel, L ^x   more..

^a Farmington   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

ⁱ PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^j DEPARTMENT OF PATHOLOGY   (United States)

^k St Luke's Hospital   (United States)

^l DANBURY HOSPITAL   (United States)

^m Atlantic Neuroscience Institute   (United States)

ⁿ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o BOSTON MEDICAL CENTER   (United States)

^p UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^s RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^t MAINE MEDICAL CENTER   (United States)

^u SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^v GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^w WADSWORTH CENTER   (United States)

^x UNIVERSITY OF CONNECTICUT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTRIAXONE; DOXYCYCLINE; PLACEBO; BACTERIUM ANTIBODY;

ANAPHYLAXIS; ARTHRITIS; BILIARY TRACT DISEASE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CHOLECYSTECTOMY; CHRONIC DISEASE; CLINICAL TRIAL; ENCEPHALOMYELITIS; ERYTHEMA CHRONICUM MIGRANS; FATIGUE; HEART DISEASE; HUMAN; LABORATORY DIAGNOSIS; LONG TERM CARE; LYME DISEASE; MENINGITIS; MUSCULOSKELETAL PAIN; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SHORT TERM MEMORY; UNSPECIFIED SIDE EFFECT; BLOOD; CEREBROSPINAL FLUID; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATIENT SELECTION;

ANTIBODIES, BACTERIAL; BORRELIA BURGDORFERI GROUP; CHRONIC DISEASE; CONTROLLED CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYME DISEASE; PATIENT SELECTION;

EID: 34948831101     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra072023     Document Type: Review

References (58)

1. Steere AC. Lyme disease. N Engl J Med 2001;345:115-24.
2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006;43:1089-134.
3. Stanek G, O'Connell S, Cimmino M, et al. European Union concerted action on risk assessment in Lyme borreliosis: clinical case definitions for Lyme borreliosis. Wien Klin Wochenschr 1996;108:741-7.
4. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31.
5. Cameron D, Gaito A, Harris N, et al. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004;2:Suppl 1:S1-S13.
6. Harvey WT, Salvato P. 'Lyme disease': ancient engine of an unrecognized borreliosis pandemic? Med Hypotheses 2003;60:742-59.
7. Burdge DR, O'Hanlon DP. Experience of a referral center for patients with suspected Lyme disease in an area of nonendemicity: first 65 patients. Clin Infect Dis 1993;16:558-60.
8. Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998;128:354-62.
9. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993;269:1812-26.
10. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990;88:577-81.
11. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.
12. Wormser GP, Dattwyler RJ, Shapiro ED, et al. Single-dose prophylaxis against Lyme disease. Lancet Infect Dis 2007;7:371-3.
13. Akin E, McHugh GL, Flavell RA, Fikrig E, Steere AC. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged arthritis and the IgG response to P35 correlates with mild and brief arthritis. Infect Immun 1999;67:173-81.
14. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993;167:392-400.
15. Klempner MS, Schmid CH, Hu L, et al. Intralaboratory reliability of serologic and urine testing for Lyme disease. Am J Med 2001;110:217-9.
16. Notice to readers: caution regarding testing for Lyme disease. MMWR Morb Mortal Wkly Rep 2005;54:125-6.
17. The laboratory diagnosis of Lyme borreliosis: guidelines from the Canadian Public Health Laboratory Network. Can J Infect Dis Med Microbiol 2007;18:145-8.
18. Donta ST. Macrolide therapy of chronic Lyme disease. Med Sci Monit 2003;9:I-136-I-142.
19. Idem. Tetracycline therapy of chronic Lyme disease. Clin Infect Dis 1997;25:Suppl 1:S52-S56.
20. Fallon BA, Tager F, Fein L, et al. Repeated antibiotic treatment in chronic Lyme disease. J Spirochetal Tickborne Dis 1999;5:94-102.
21. Food and Drug Administration. Warning on bismacine. FDA Consumer 2006;40:5.
22. Imported malaria associated with malariotherapy of Lyme disease - New Jersey. MMWR Morb Mortal Wkly Rep 1990;39:873-5.
23. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006;55(RR-11):1-94.
24. Wessely S. Chronic fatigue: symptoms and syndrome. Ann Intern Med 2001;134:838-43.
25. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43:1078-86.
26. Nieman GF, Zerler BR. A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 2001;8:317-25.
27. Lightfoot RW Jr, Luft BJ, Rahn DW, et al. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic test for Lyme disease: a cost-effectiveness analysis. Ann Intern Med 1993;119:503-9.
28. Tugwell P, Dennis DT, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 1997;127:1109-23.
29. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003;115:91-6.
30. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005;34:1340-5.
31. Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP. Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol 2005;34:1437-9.
32. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.
33. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003;60:1923-30.
34. Kaplan RF, Trevino RP, Johnson GP, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology 2003;60:1916-22.
35. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995;171:356-61.
36. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis 2000;31:1107-9.
37. Fallon BA, Sackheim HA, Keilp J, et al. Double-blind placebo-controlled retreatment with IV ceftriaxone for Lyme encephalopathy: clinical outcome. Presented at the 10th International Conference on Lyme Borreliosis and Other Tick-Borne Diseases, Vienna, Austria, September 11-15, 2005.
38. Wormser GP, Dattwyler RJ, Shapiro E, et al. Reply to Pollack, Donta, Wilson and Arnez. Clin Infect Dis 2007;44:1137-9.
39. Phillips SE, Mattman LH, Hulinská D, Moayad H. A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated. Infection 1998;26:364-7.
40. Klempner MS. Controlled trials of antibiotic treatment in patients with posttreatment chronic Lyme disease. Vector Borne Zoonotic Dis 2002;2(4):255-63.
41. Marques AR, Stock F, Gill V. Evaluation of a new culture medium for Borrelia burgdorferi. J Clin Microbiol 2000;38:4239-41.
42. Tilton RC, Barden D, Sand M. Culture of Borrelia burgdorferi. J Clin Microbiol 2001;39:2747.
43. Bayer ME, Zhang L, Bayer MH. Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms: a PCR study of 97 cases. Infection 1996;24:347-53.
44. Rauter C, Mueller M, Diterich I, et al. Critical evaluation of urine-based PCR assay for diagnosis of Lyme borreliosis. Clin Diagn Lab Immunol 2005;12:910-7.
45. Hellyer TJ, Fletcher TW, Bates JH, et al. Strand displacement amplification and the polymerase chain reaction for monitoring response to treatment in patients with pulmonary tuberculosis. J Infect Dis 1996;173:934-41.
46. Morgen K, Martin R, Stone RD, et al. FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. Neurology 2001;57:1980-5.
47. Asch ES, Bujak DI, Weiss M, Peterson MG, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 1994;21:454-61.
48. Sigal LH, Patella SJ. Lyme arthritis as the incorrect diagnosis in pediatric and adolescent fibromyalgia. Pediatrics 1992;90:523-8.
49. Wormser GP. Lyme disease: insights into the use of antimicrobials for prevention and treatment in the context of experience with other spirochetal infections. Mt Sinai J Med 1995;62:188-95.
50. Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology 2000;146:119-27.
51. Livengood JA, Gilmore RD Jr. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect 2006;8:2832-40.
52. Pachner AR, Gelderblom H, Cadavid D. The rhesus model of Lyme neuroborreliosis. Immunol Rev 2001;183:186-204. [Erratum, Immunol Rev 2002;187:139.]
53. Pal U, Fikrig E. Adaptation of Borrelia burgdorferi in the vector and vertebrate host. Microbes Infect 2003;5:659-66.
54. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
55. Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006;367:346-55.
56. Richardson RD, Engel CC Jr. Evaluation and management of medically unexplained physical symptoms. Neurologist 2004;10:18-30.
57. Sigal LH, Hassett AL. Contributions of societal and geographical environments to "chronic Lyme disease": the psychopathogenesis and aporology of a new "medically unexplained symptoms" syndrome. Environ Health Perspect 2002;110:607-11.
58. Renfro L, Feder HM Jr, Lane TJ, Manu P, Matthews DA. Yeast connection among 100 patients with chronic fatigue. Am J Med 1989;86:165-8.